GlassScriptPhysician profile
Gordon Mitchell Layton
NPI 1356075261
$3,206.60
in general payments reported to CMS, 2019-2025
17 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,289 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,206.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.91 | 2024-2025 | |
| Lilly USA, LLC | $436.03 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $348.53 | 2024-2025 | Spravato |
| Novo Nordisk INC | $329.97 | 2024-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $318.28 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $238.87 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $209.65 | 2024-2025 | Caplyta |
| Almatica Pharma LLC | $192.85 | 2024-2025 | Loreev Xr |
| Amgen INC. | $187.15 | 2024-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.31 | 2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $150.00 | 2024-2025 | Qelbree |
| Exact Sciences Corporation | $52.99 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.63 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $18.83 | 2024 | Rexulti |
| Corcept Therapeutics | $17.81 | 2025 | Korlym |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $17.18 | 2025 | Contrave |
| Inspire Medical Systems, INC. | $15.61 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gordon Layton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.